Pharming Group N.V.

NASDAQ:PHAR

Biotechnology

Healthcare
$12.48 +2.19%

+$0.28 today

Market cap
$882.43M
Beta
0.10
P/E (TTM)
77.0
EPS (TTM)
$0.02
52W Low $9.54High $21.34

Volume 0.01M

Average 0.01M

PHAR Net Income

Bottom-line profit, the starting point for calculating cash from operations.

Pharming Group N.V.NASDAQ: PHAR

Net Income · Q1 FY2026 · quarter ended Mar 2026

Net income dips below year-ago levels

Q1 FY2026 net income of $5.23M (cash outflow) fell 55.6% year over year, behind the +298.9% change in trailing-twelve-month net income. Over 3 fiscal years it compounded at -42.4% a year.

Context

  • Net income amounted to 0.8% of revenue in FY2025, down 2.1 pp from a year earlier.
  • Net income increased in 2 of the last 3 fiscal years.

What to watch

Whether net income reaches the consensus estimate from 3 analysts of $25.13M (+779.1%) for the fiscal year ending Dec 2026, a step up from the +132.5% reported in FY2025.

Sources:Cash Flow Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
-$5.23M-198.8% QoQ
Last fiscal yearDec 2025
$2.86M+132.5% YoY
LTMMar 2026
$14.61M+298.9% YoY
Net Income past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-55.6%-33.5%+22.1 pp
1 year+132.5%+779.1%+646.6 pp
3-year CAGR-42.4%+148.7%+191.1 pp
5-year CAGR+69.4%—
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Net Income history

USD · from the cash flow

Latest · FY2025
2.86M USD
Year-over-year change
+132.5%
4-year CAGR
-42.5%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Net Income vs competitors

How PHAR compares with its peers on the latest reported figures

  • Peers report in different currencies, so net income is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +298.9% is the 3rd highest of 9, against a peer median of +31.1%.
  • Net income amounts to 4.0% of revenue for PHAR, versus a peer median of 339.4%.
PHAR Competitors
Net Income for PHAR and competitors
Company Period LTM YoY 3-year CAGR% of revenue
BMRNBioMarin Pharmaceutical Inc.LTM Sep 2026$27.6B USD+3808.4%+35.1%2.7%
IONSIonis Pharmaceuticals, Inc.LTM Sep 2026$546.15M USD+113.1%+12.2%56.9%
NTLAIntellia Therapeutics, Inc.LTM Mar 2026$500.92M USD-4.8%+3.1%757.9%
BCRXBioCryst Pharmaceuticals, Inc.LTM Jun 2026$268.25M USD+651.2%—28.5%
RCKTRocket Pharmaceuticals, Inc.LTM Mar 2026$209.38M USD-18.9%+0.2%—
PHVSPharvaris N.V.LTM Sep 2026€179.96M EUR+11.0%+31.9%—
STOKStoke Therapeutics, Inc.LTM Mar 2026$169.77M USD-437.7%-59.2%529.2%
SLNSilence Therapeutics plcLTM Mar 2026$145.44M USD—+20.7%15782.6%
PRQRProQR Therapeutics N.V.LTM Mar 2026€45.62M EUR+51.2%-14.2%339.4%
PHARPharming Group N.V.LTM Mar 2026$14.61M USD+298.9%-42.4%4.0%
Peer median (excluding PHAR) —+31.1%+7.6%339.4%

Competitors are the stored peer set for PHAR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income26.16M14.99M(12.01M)(8.79M)2.86M
Depreciation & Amortization22.23M13.19M15.93M16.64M0
Deferred Income Tax00000
Stock-Based Compensation10.27M6.39M9.25M11.65M0
Change in Working Capital(5.62M)(387K)(16.96M)(10.43M)14.4M
Accounts Receivables6.71M2.36M(18.54M)(7.02M)(3.36M)
Inventory(6.98M)(15.02M)(14.43M)(520.85K)(1.29M)
Accounts Payables000017.87M
Other Working Capital(5.36M)12.27M16.01M(2.88M)1.19M
Other Non-Cash Items(10.14M)(11.72M)(13.51M)(10.92M)32.8M
Operating Cash Flow42.9M22.46M(17.3M)(1.86M)50.07M
Capital Expenditures(18.95M)(1.98M)(1.46M)(824.25K)(751.09K)
Acquisitions (Net)07.3M00(65.53M)
Purchases of Investments(5.2M)0(382.01M)(294.4M)0
Sales of Investments00232.81M327.97M0
Other Investing Activities0021.28M084.72M
Investing Cash Flow(24.15M)5.32M(129.39M)32.74M18.43M
Debt Repayment(3.65M)(3.31M)(4.04M)(35.61M)0
Common Stock Issued5.35M2.28M0019.87M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities(33.39M)(3.95M)3M(19.67K)(5.39M)
Financing Cash Flow(31.68M)(4.98M)(1.04M)(35.63M)14.48M
Effect of Forex Changes(2.07M)(7.38M)2.13M(2.29M)8.12M
Net Change in Cash(15M)15.42M(145.6M)(7.04M)91.09M
Free Cash Flow23.95M20.48M(18.77M)(2.68M)49.31M

Pharming Group N.V.

NASDAQ:PHAR

Intrinsic Alpha fair value

Locked

Current Price

$12.48

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.